Strong sales performance and solid momentum with the Phase 3 trial in anti-GBM disease Cash runway extended into 2026 Evan Ballantyne joins Hansa Biopharma as Chief Financial Officer LUND, Sweden, April 18, 2024 /PRNewswire/ — Hansa Biopharma, the pioneer in immunomodulatory enzyme…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.